DADahiana Amarillo

Dahiana Amarillo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dahiana Amarillo has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overlap Syndrome of Myocarditis–Myositis– Myasthenia Induced by Immunotherapy in Advanced Melanoma: A Case Report

    by Agustin Cabillon, Natalia Camejo, Dahiana Amarillo, Federico Garcia, Virginia Suaya, Cecilia Castillo, Gabriel Krygier

    Immune checkpoint inhibitors have transformed the treatment of advanced melanoma; however, they may be associated with potentially severe immune-related adverse events. Among these, myocarditis–myositis– myasthenia overlap syndrome (MMM) is a rare but highly life-threatening condition. We report the case of an 84-year-old patient with stage IV melanoma treated with nivolumab and ipilimumab using a reduced-dose regimen, who initially developed immune-mediated hepatitis, followed by proximal muscle weakness, bulbar involvement, and myasthenic symptoms, associated with markedly elevated creatine kinase levels. During hospitalization, the patient developed complete atrioventricular block and significant troponin elevation, consistent with MMM overlap syndrome. Treatment with high-dose intravenous methylprednisolone followed by oral corticosteroids and pyridostigmine was initiated, resulting in favorable clinical evolution, with neurological improvement and hemodynamic stabilization without the need for second-line therapies. This case highlights the importance of early recognition of severe immune- related adverse events, the need for a multidisciplinary approach, and prompt initiation of immunosuppressive therapy, which may significantly improve clinical outcomes even in elderly patients.

  • Open Access

    Efectos adversos inmunomediados en pacientes portadores de tumores sólidos tratados con bloqueadores de puntos de control inmunológico en cuatro centros de Montevideo, Uruguay

    by Daniela Amarillo, Mathías Jeldres, Clara Rodríguez, Sofía Acuña, Belén Ayala, Florencia Rivero, Esteban Roca, Felipe Sellanes, Sofía Collares, Paula Ghiringhelli, et al.

    Introducción: La inmunoterapia es una estrategia clave en la terapia oncológica actual y sus indicaciones con fines curativos o paliativos siguen creciendo. Su objetivo es fortalecer la respuesta inmune efectora contra las células tumorales con un perfil de efectos adversos diferente al de los tratamientos convencionales. En este trabajo evaluamos el perfil y la frecuencia de efectos adversos inmunomediados de los inhibidores de puntos de control inmunológico (ICI), en pacientes de 4 instituciones de Montevideo. Metodología: Estudio observacional, descriptivo, transversal y retrospectivo. Se analizaron los datos de pacientes portadores de tumores sólidos que recibieron tratamiento con inhibidores del punto de control inmunológico en cuatro centros asistenciales de Montevideo, Uruguay, en el periodo comprendido entre 2021-2024. Resultados: El 49,5% (n=47) de los pacientes tratados en monodroga (ICI, ICI+ICI) presentaron efectos adversos, 64,3% (n=9) de aquellos tratados con ICI en combinación con ITK y 67,4% (n=33) de quienes recibieron ICI en combinación con QT. En términos generales, el estudio evidenció que la población se comporta de forma similar a los registros publicados. Conclusiones: El creciente uso de los inhibidores de punto de control inmune (inmunoterapia) en el tratamiento del cáncer, trae aparejado la aparición de un nuevo tipo de efectos adversos, conocidos como efectos adversos inmuno relacionados o irAEs. En este trabajo se reportaron los efectos adversos vinculados al tratamiento con inmunoterapia en cuatro centros de Montevideo, Uruguay. El porcentaje de irAEs descrito en este estudio coincide con los reportados en los ensayos clínicos y revisiones sobre el tema.

  • Open Access

    [Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].

    by Natalia Camejo-Martínez, Noelia Strazzarino-Peluffo, Dahiana Amarillo-Hernández C, Cecilia Castillo-Leska, Gabriel Krygier-Waltier

    Ribociclib improves progression-free and overall survival (PFS and OS) in women with advanced HR+/HER2- breast cancer (BC), but real-world evidence in Uruguay is limited. To describe the clinical characteristics, outcomes, and safety profile of women with advanced HR+/HER2- breast cancer treated with ribociclib plus hormone therapy in Uruguay. Observational, retrospective study. Demographic and clinical variables, type of hormone therapy, treatment duration, and adverse events were analyzed. A total of 54 patients from public and private institutions were included, with a median age of 60 years. 67% relapsed after adjuvant treatment. Bone was the most common metastatic site (72%). Ribociclib was administered as first-line treatment in 81% of cases, and combined with aromatase inhibitors in 63%. The mean OS was 41.6 months and the mean PFS was 30 months; medians were not reached. Neutropenia was the most frequent adverse event (66%), followed by gastrointestinal toxicity (nausea 33%, diarrhea 28%) and skin toxicity (16%). One death due to pulmonary embolism was recorded, and QTc prolongation was documented in 5.6% of patients. Dose reduction was required in 20%, and one patient discontinued treatment due to skin toxicity. Ribociclib was well tolerated, with a safety profile consistent with the literature. This study provides relevant local evidence and supports its use in real-world settings. Longer follow-up is needed to more accurately assess OS and PFS outcomes.

  • Open Access

    Perfil molecular del adenocarcinoma gástrico y de la unión gastroesofágica

    by Edward Delgado, Dahiana Amarillo, Ulises Parada, Fabrizzio Girardi, Agustin Felipez, Roberto Taruselli

    El cáncer gástrico corresponde a unos de los tumores malignos del tubo digestivo más frecuentes. En nuestro medio generalmente se presenta en etapas avanzadas. En estos pacientes el avance en la caracterización histopatológica y molecular ha motivado la implementación de terapias dirigidas, la asociación con quimioterapia ha demostrado un aumento significativo de la sobrevida en pacientes con enfermedad diseminada. Objetivo: Realizar una descripción epidemiológica, clínica, patológica y molecular de los tumores gástricos y de la unión gastroesofágica en una cohorte retrospectiva en el período del 1 de enero de 2019 al 31 de octubre de 2024, Hospital de Clínicas, Montevideo, Uruguay. Metodología: Se realizó un estudio descriptivo, observacional y retrospectivo en un período de 5 años. Se recabaron los datos de todos los pacientes diagnosticados y tratados por cáncer gástrico en el Hospital de Clínicas Dr. Manuel Quíntela, los cuales presentaron una muestra archivada en el Departamento de Anatomía Patológica. Resultados: Se obtuvo una muestra de 59 pacientes. En 26 de ellos se logró analizar PD-L1 con 10 pacientes positivos y 16 negativos. La expresión de Her-2/neu se obtuvo en 49 pacientes con 28 score 0, 4 Her-2/neu +, 9 Her2/neu ++ y 8 Her2/neu +++.La inestabilidad microsatelital (MSI) se analizó en 34 pacientes, 10 presentaron MSI- H/dMMR y 24 baja probabilidad de MSI. Conclusiones: Se logró realizar la caracterización molecular y epidemiológica de los pacientes con adenocarcinoma gástrico y de la unión esofagogástrica. Destacamos se trata del primer estudio en Uruguay en caracterizar molecularmente estos tumores con el fin de realizar terapias oncológicas dirigidas a cada subtipo molecular (Oncoespecíficas).

  • Influence of different treatment modalities on the sexual function of breast cancer survivors: An observational ambispective study

    by Natalia Camejo Martinez, Cecilia Castillo Leska, María Rosina Servetto Martinez, Miriam Gianina Muñoz Arce, Joaquín Manzanares Cuevas, Dahiana Lourdes Amarillo Hernández, María Gabriela Guerrina Valeta, Guadalupe Rocío Herrera Álvarez, María Carolina Dörner Cabrera, Gabriel David Krygier Waltier

    Introduction Advances in treatment have improved the survival rates of patients diagnosed with breast cancer. However, the number of women experiencing long-term consequences has also increased, affecting their quality of life, including sexual function. Objectives To evaluate the prevalence of sexual dysfunction as measured by the Female Sexual Function Index, its association with treatment modalities in Uruguayan breast cancer survivors, and to compare the questionnaire scores by age group (50 years or older versus under 50 years). Methods This ambispective observational study included patients diagnosed with early-stage breast cancer (I to III) who had completed surgery, chemotherapy, and radiotherapy treatments at least 12 months before inclusion. Patients completed the Female Sexual Function Index questionnaire, and the data were analyzed using simple and multiple binary logistic models to assess the relationship between treatment modalities and sexual dysfunction. Additionally, differences in Female Sexual Function Index scores between age groups were analyzed. Results A total of 149 patients were included; 67.1% underwent breast-conserving surgery, 68.5% received chemotherapy, 92.6% radiotherapy, and 95.3% hormone therapy. Sexual dysfunction, defined as a score ≤ 26.55 on the questionnaire, was present in 58.3% of patients. Multivariate analysis indicated a higher risk of sexual dysfunction in patients who underwent total mastectomy, were treated with chemotherapy, or used gonadotropin-releasing hormone agonists. Conclusions Although this study highlights the impact of certain treatment modalities on sexual function, the results should be interpreted considering the characteristics of the population and potential biases. These findings can guide clinicians in planning treatments to improve the quality of life of sexually active breast cancer patients.

  • Fulvestrant in clinical practice: Effectiveness analysis in Uruguayan patients with HR+/HER2- breast cancer

    by Natalia Camejo, Dahiana Amarillo, Cecilia Castillo, Sofía Badía Alza, Camila Baliño, Miguel Banchieri, Juan Fagundez, Santiago Ghiga, Marcos Lorier, Isabel Alonso, et al.

    Introduction Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies. Methods A database from the National Resources Fund covering the period from 2009 to 2022 was used. Survival curves were assessed using the Kaplan-Meier method, and differences were analyzed using the Log-Rank test. Results A total of 1085 patients with an average age of 63,66 years were included. Following a follow-up of 14 months, the median overall survival was 16 months, and the median progression-free survival was 6 months. The presence of liver and bone metastases was associated with a shorter overall survival. Patients from the public sector and those with a better performance status experienced longer overall survival. Conclusions Our findings provide a valuable perspective for treatment management in a context of limited resources. Overall survival and progression-free survival were somewhat lower than those reported in pivotal clinical trials. The presence of liver and bone metastases was associated with worse prognosis and survival; additionally, patients with worse performance status had shorter overall survival. These findings underscore the need for personalized therapies, opening new lines of future research.

  • Open Access

    Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice

    by Natalia Camejo, Cecilia Castillo, Dahiana Amarillo, Heber de Los Santos, Gaston Samurio, Ahinara Silva-Marquez, Franco Sosa, Claudia Vera, Rocio Xavier, Guadalupe Herrera, et al.

    Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice

  • Open Access

    [Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer].

    by Natalia Camejo-Martínez, Cecilia Castillo-Leska, Valeria Rodríguez-Saenz, Guadalupe Herrera-Álvarez, Dahiana Amarillo-Hernández, María Carolina Dörner-Cabrera, Gabriel Krygier-Waltier

    HER-2 positive (+) breast cancer (BC) accounts for 20-25% of BC, it is more aggressive, and it has a lower survival rate. Since the approval of trastuzumab in 1998, other HER-2-targeted therapies such as pertuzumab and trastuzumab emtansine (TDM1) have been introduced, improving patient survival. However, cardiotoxicity is an adverse effect of these treatments. To estimate the incidence of cardiotoxicity with trastuzumab, trastuzumab/pertuzumab, and TDM1 in women with HER-2 + BC treated over a 6-year period at the Hospital de Clínicas and the Hospital Departamental de Soriano. Observational, descriptive, and retrospective study which included patients with HER-2 + BC treated with trastuzumab, trastuzumab/pertuzumab, or TDM1. 81 patients were included, with a cardiotoxicity incidence of 23.4%. Cardiotoxicity was determined by a > 10% decrease in left ventricular ejection fraction (LVEF) (57.9%) and a LVEF < 50% evident during treatment (42.1%). Only 1 patient presented symptomatic heart failure. 63.1% of those who discontinued treatment due to cardiotoxicity managed to resume it. No relationship was evident between cardiovascular history or the administration regimen and the development of cardiotoxicity. The study showed a cardiotoxicity incidence similar to the international one. Most did not present cardiac toxicity, and if they did, it was asymptomatic and reversible.


  • Open Access

    Hormone therapy adherence in breast cancer: Predictive factors in Uruguay

    by Natalia Camejo, Cecilia Castillo, Lucía Argenzio, Diego Santana, Dahiana Amarillo, Guadalupe Herrera, María Guerrina, Carolina Dörner, Gabriel Krygier

    Background/Aim: Adjuvant hormone therapy (HT) significantly improves survival in patients with hormone receptor-positive breast cancer, yet adherence to this therapy is critical and tends to decrease over time. This study aims to identify risk factors for suboptimal adherence to adjuvant HT among patients treated at the Hospital de Clínicas and the Hospital Departamental de Soriano, Uruguay, to inform future strategies to improve adherence. Materials and Methods: A retrospective, cross-sectional study was conducted, including 96 breast cancer patients in stages I-III treated with HT for at least three years. Adherence was assessed using the Morisky-Green questionnaire. Statistical analysis was employed to estimate the odds ratios (OR) for non-adherence, with a significance threshold of α=0.05. Results: Out of the 96 patients included, 22.9% demonstrated suboptimal adherence to hormone therapy. Analysis revealed that the use of tamoxifen (adjusted OR of 4.86, p<0.05) and living with others were significant predictors of non-adherence. The aggressiveness of the treatment did not show a statistically significant correlation with adherence. Additionally, the analysis highlighted that sociodemographic characteristics, such as marital status and employment situation, did not directly influence adherence, underscoring the complexity of factors contributing to treatment adherence. Intriguingly, the analysis showed a trend towards greater adherence among postmenopausal patients and those with a history of combined treatment of tamoxifen and aromatase inhibitors, though these results warrant further exploration. Conclusion: Suboptimal adherence to adjuvant HT in breast cancer patients is significantly influenced by the type of hormone therapy prescribed and the patient's social environment. It is necessary to develop personalized interventions that address these factors to improve adherence.

  • Open Access

    Características clinicopatológicas e índice de masa corporal en mujeres Uruguayas portadoras de cáncer de mama asistidas en el Hospital de Clínicas

    by Natalia Camejo, Dahiana Amarillo, Florencia Ceriani, Lidia De León Manfrú, Florencia De Olea, Mauricio Diaz, Franco Donato, Alexandra Suarez, Rocio Tamborindeguy, Cecilia Castillo, et al.

    Objetivo. Describir las características clinicopatológicas del cáncer de mama (CM) en mujeres con sobrepeso/obesidad y su manejo en la práctica clínica, en pacientes uruguayas asistidas en Servicio de Oncología del Hospital de Clínicas. Material y métodos. Estudio observacional, descriptivo, retrospectivo de corte transversal, que incluyó a pacientes con diagnóstico de CM del centro ya mencionado, desde enero de 2020 a mayo de 2022. Se evaluaron las variables demográficas, índice de masa corporal, subtipo histológico, receptores hormonales, HER 2neu y tratamiento recibido. Pruebas estadísticas: media y desvío estándar. Analíticas: Chi cuadrado para variables cualitativas y test de Student para variables cuantitativas. Resultados. Se incluyeron 141 pacientes, 56% presentaba sobrepeso/obesidad. La mediana de edad al momento del diagnóstico fue similar para ambos grupos: 58 vs. 58.8 años (p =0.762). Entre las pacientes con sobrepeso/obesidad fueron más frecuente: el carcinoma ductal (p = 0.005); los tumores luminales, aunque sin significancia estadística, y la mastectomía (p =0.012). Mientras que entre las pacientes con normopeso fueron más frecuente: el carcinoma lobulillar (p = 0.043), los tumores triple negativos si bien estos valores no fueron estadísticamente significativos y la cirugía conservadra (CC) (p =0.012).La proporción de pacientes que presentaron recaída fue similar en ambos grupos (p =0.48). Conclusiones. En nuestro estudio el sobrepeso y la obesidad no se relacionaron con la mayoría de las características del CM, pero sí en el tipo histológico y tipo de tratamiento quirúrgico. No se observaron diferencias significativas en la tasa de recaída entre los dos grupos de pacientes.